2014 Chabner Colloquium: Collaboration in Cancer Drug Trials
2014 Chabner Colloquium: Collaboration in Cancer Drug Trials
215 Charles Street
Boston, MA 02114 (map)
Monday - Tuesday, November 10 - 11, 2014
In the field of oncology, the rapid pace of discovery and a better understanding of prevention, detection, the microenvironment, and treatment of cancer will lead to improved patient outcomes. Accurately tailored cancer treatment and individualized therapy will focus on tumor biology and host factors. The healthcare provider will need to be well informed in order to provide the most effective therapy for a particular patient with the fewest associated risks and toxicities. In oncology, our understanding of the complexity of the disease is expanding at an exponential rate.
After successful completion of this educational activity, participants should be able to:
· Explain the use of testing for EGFR mutations at diagnosis of NSCLC.
· Explain the role of stress response pathways in the metabolic homeostasis of pancreatic cancer cells.
· Discuss the molecular mechanisms regulating metabolism of cancer cells.
· Describe the function of the mammalian sirtuin SIRT6, a histone deacetylase, in controlling expression of key metabolic and ribosomal genes during oncogenic transformation.
· Discuss interpatient heterogeneity of advanced prostate cancer, clonal evolution with treatment, mechanisms of treatment resistance, and the use of novel therapeutic strategies.
· Describe the role of immunotherapy in the treatment of cancer.
· Explain the mechanisms of action for immune checkpoint antibodies.
· Cite the side effects and management strategies for immune checkpoint antibodies.
· Describe the landscape of recurrently mutated genes in AML.
· Discuss the implications of intra-patient clonal heterogeneity in AML.
· Review the somatic mutations that predict prognosis in MDS independent of existing clinical parameters.
· Describe the key biological processes that are altered by genetic mutations in MDS, including RNA splicing, cohesin ring function, epigenetic regulation, kinase signaling, and transcription factors.
· Discuss the molecular basis of lenalidomide activity in MDS.
· Explain the biologic and prognostic role of TET2/IDH mutations in leukemia.
· Explain the role of epigenetic therapies in TET2/IDH-mutant leukemias.
· Describe the potential use of molecular analysis of circulating tumor cells for drug development in breast cancer.
· Discuss the mechanisms of resistance to targeted therapies in lung cancer.
· Explain the pathogenesis of IDH mutant cholangiocarcinoma.
· Discuss EZH2 inhibition as a therapeutic target in SWI/SNF altered malignancies.
· Discuss the translational implications of the finding that RNF43 is a frequently mutated gene in colorectal and endometrial cancers.Describe the role of serine metabolism in cancer.
· Discuss the use of antifolates and related targets for cancer therapy.
· Explain the prevalence of consequences of methylthioadenosine phosphorylase (MTAP) deficiency in cancer.
· Describe the role of inhibitors of de novo purine synthesis (e.g., thioguanine) and their potential as effective treatment for patients with cancers lacking MTAP.
· Explain the role of mitochondria in the proper functioning of cellular one-carbon metabolism.
· Describe the relationship between one-carbon defects and mitochondrial disease manifestation.
· Cite current genomic methods for profiling human tumors.
· Describe the benefits and limitations of genomically focused clinical trial designs.
This activity is designed to meet the educational needs of physicians and scientists in academic and practice settings who wish to advance their knowledge of the research into new treatments and improve their competence in the care of patients with cancer.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Society for Translational Oncology and The Massachusetts General Hospital. The Society for Translational Oncology is accredited by the ACCME to provide continuing medical education for physicians.
The Society for Translational oncology designates this live activity for a maximum of 10 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
In order to receive CME credit, learners must sign-in, review the CME information (accreditation, learning objectives, faculty disclosures, etc.) and attend the CME activity. Learners will be asked to complete an electronic activity evaluation following the meeting and indicate the number of credit hours claimed. Certificates will be provided upon completion of the evaluation.
To obtain CME credit, please visit: http://bit.ly/2014ChabnerCMECredit.
In accordance with ACCME Standards for Commercial Support and the policies of the Society for Translational Oncology (STO), persons participating in this activity who are in a position to control the content have disclosed all relevant relationships with any commercial interest. On the basis of disclosed information, STO identifies and resolves all conflicts of interest before delivery of content.
STO staff involved in the development of this activity have nothing to disclose.
The following faculty have indicated that they have had relevant financial relationship(s) with a commercial interest within the past 12 months or that they have nothing to disclose.
Robert Bao, PhD; Nothing to disclose
Aaron N. Hata, MD, PhD; Honoraria: Amgen, Inc
Nabeel Bardeesy, MD; Nothing to disclose
F. Stephen Hodi, Jr, MD; Consultant/advisory role: (Uncompensated) Bristol-Myers Squibb, Merck, Genentech, Novartis. Research funding: (Funds to institution) Bristol-Myers Squibb, Merck, Genentech, Novartis
Aditya Bardia, MD, MPH; Nothing to disclose
John Iafrate, MD; Intellectual property right/Inventor/patent: Bioreference Labs and Enzymatics INC. Consultant/advisory role: Enzymatics, Constellation, Chugai and DebioParm. Ownership interest: Enzymatics
Joseph R. Bertino, MD; Nothing to disclose
Ross L. Levine, MD; Consultant/advisory role: Agios Pharmaceuticals
Bruce A. Chabner, MD; Consultant/advisory role: Merrimack Pharmaceuticals, Sanofi, Epizyme. Employment: PharmaMar (Board of Directors). Expert testimony: Eli Lilly. Ownership interests: PharmaMar (Zeltia), Pharmacyclics, Gilead, Exelixis, Celgene, Seattle Genetics
Raul Mostoslavsky, MD, PhD; Nothing to disclose
Gregory M. Cote, MD, PhD; Consultant/advisory role: Advance Medical. Research funding: Chordoma Foundation
Steven A. Rosenberg, MD, PhD; Nothing to disclose
Johann S. de Bono, MB ChB, FRCP, MSc, PhD ; Consultant/advisory role: Johnson & Johnson, Astellas, Medivation, AstraZeneca, Sanofi. Research funding: AstraZeneca, Sanofi, Genentech
David Ryan, MD; Consultant/advisory role: MedImmune, LLC
Benjamin L. Ebert, MD; Consultant/advisory role: Genoptix, Inc, Celgene. Research funding: Celgene
Supriya Saha, MD, PhD; Nothing to disclose
Soldano Ferrone, MD, PhD; Nothing to disclose
David Solit, MD; Consultant/advisory role: Pfizer, Inc
Keith Flaherty, MD; Employment: Clovis Oncology (Board of Directors), Loxo Oncology (Board of Directors). Consultant/advisory role: Glaxo SmithKline, Roche, Sanofi, Momenta, Astex, Ziophram and Viralytics
Matthew Vander Heiden, MD, PhD; Consultant/advisory role: Agios Pharmaceuticals. Ownership interest: Agios Pharmaceuticals
Marios Giannakis, MD, PhD; Nothing to disclose
Timothy A. Graubert, MD; Consultant/advisory role: Genoptix, Inc
Monday, November 10, 2014
8:00 a.m. Welcome and Introductions: Martin J. Murphy, DMedSc, PhD, Convener, Society for Translational Oncology
Session 1: New Insights into Metabolic Regulation of Cancer Growth – Bruce A. Chabner, MGH, Moderator
Nabeel Bardeesy (MGH)
Insights into Pancreatic Cancer Metabolism
Raul Mostoslavsky (MGH)
The Histone Deacetylase SIRT6: Linking Epigenetics to Cancer Metabolism
Johann de Bono (ICR, Royal Marsden, Surrey, UK)
Improving the Treatment of Prostate Cancer
10:30a.m. – 10:45 a.m. Beverage Break
Session 2: Immunotherapy – Soldano Ferrone, MGH, Moderator
Steven A. Rosenberg (NCI)
Curative Potential of Cell Transfer Immunotherapy for Cancer
F. Stephen Hodi, Jr (DFCI)
Immune Checkpoint Therapy
12:30p.m. – 1:30 p.m. Lunch Buffet (provided by STO)
Session 3: Hematological Malignancies - Timothy A. Graubert, MGH, Moderator
Timothy A. Graubert (MGH)
Molecular Profile of Acute Myeloid Leukemia (AML)
Benjamin L. Ebert (BWH)
Understanding Myelodysplastic Syndromes (MDS)
Ross L. Levine (MSKCC)
Pathogenesis and Therapy of IDH/TET- mutant Myeloid Malignancies
3:45 p.m. – 4:00 p.m. Beverage Break
Session 4: Junior Faculty Forum - Joseph R. Bertino, RCI, Moderator
Aditya Bardia (MGH)
Molecular Interrogation of Circulating Tumor Cells for Drug Development in Breast Cancer
Aaron N. Hata (MGH)
Evolution of Acquired Resistance to Targeted Therapies in Lung Cancer
Supriya Saha (MGH)
From Model Systems to Novel Therapeutics: Understanding IDH Mutant Cholangiocarcinoma
Gregory M. Cote (MGH)
Targeting EZH2 in SWI/SNF Altered Sarcomas
Marios Giannakis (DFCI)
Late Breaking Advances: RNF43 Mutations in Colorectal and Endometrial Cancers
5:20 p.m. Adjourn Day 1
Tuesday, November 11, 2014
7:50 a.m. Welcome and Introductions, Day 2: Martin J. Murphy, DMedSc, PhD, Convener, Society for Translational Oncology
Session 5: Metabolic Lesions in Cancer - David Ryan, MGH, Moderator
Matthew Vander Heiden (MIT)
Serine Metabolism and Cancer
Joseph R. Bertino (RCI)
Exploiting Methylthioadenosine Phosphorylase Deletion in Cancer
Robert Bao (MGH)
Systematic Analysis of the Cellular Response to Mitochondrial Dysfunction
10:15 a.m. -10:30 a.m. Beverage Break
Session 6: Genetic Profiling for Treatable Mutations - Keith Flaherty, MGH, Moderator
A. John Iafrate (MGH)
Advances in Molecular Screening: NGS
David Solit (MSKCC)
Lessons From the Study of Extraordinary Responders
Bruce A. Chabner (MGH)
12:15 p.m. – Adjourn Day 2, Lunch Buffet
STO gratefully acknowledges educational grants in partial support of this activity from:
Chugai Academy for Advanced Oncology (CHAAO)
Lilly USA, LLC
Merrimack Pharmaceuticals, Inc.
Novartis Pharmaceuticals Corporation
Prometheus Laboratories, Inc
Sigma-Tau Pharmaceuticals, Inc
Americans With Disabilities (ADA)
If disability accommodations (e.g., communication access, alternate formats) are needed to participate fully in this event, please contact [name] at [phone number and email address].
*THE PHYSICIAN PAYMENTS SUNSHINE ACT (SUNSHINE ACT) COMPLIANCE
Effective August 1, 2013, The Centers for Medicare & Medicaid Services (CMS) required reporting of any direct or indirect payments made to any US Healthcare Professional by pharmaceutical and device manufacturers and applicable group purchasing organizations (GPOs) under its Open Payments program.
In order to comply with the requirements of the pharmaceutical and device manufacturers who have provided support for this CME activity, no food and beverage costs associated with this activity have been covered by their funding. Therefore, there has been no indirect payment or transfer of value for your attendance at this meeting. NO data regarding your participation at this meeting will be reported to CMS.